A global response to the chronic shortfall in antibiotic innovation is urgently needed to
    combat antimicrobial resistance. Here, we introduce CARB-X, a new global publicâ€“private
    partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
